ACADIA Pharmaceuticals

ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (CNS) disorders. All of ACADIA's product candidates emanate from internal discoveries. We believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. ACADIA’s history is rooted in science and strong leadership in CNS research. Our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. Since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. ACADIA is headquartered in San Diego. The city represents the second largest biotechnology industry cluster in the United States, home to over 400 companies, as well as the Salk Institute for Biological Studies and the Scripps Research Institute.
San Diego, US
Size (employees)
370 (est)
ACADIA Pharmaceuticals was founded in 1993 and is headquartered in San Diego, US

ACADIA Pharmaceuticals Office Locations

ACADIA Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
300 3611 Valley Centre Dr

ACADIA Pharmaceuticals Data and Metrics

ACADIA Pharmaceuticals Financial Metrics

ACADIA Pharmaceuticals's revenue was reported to be $17.3 m in FY, 2016 which is a 28311% increase from the previous period.
$, USD

Revenue (FY, 2016)

17.3 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

14.3 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(271.4 m)

EBIT (FY, 2016)

(272.8 m)

Market capitalization (23-Jun-2017)

3.6 b

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

163.6 m
ACADIA Pharmaceuticals's current market capitalization is $3.6 b.
$, USDFY, 2013FY, 2014FY, 2015FY, 2016


1.1 m120 k61 k17.3 m

Revenue growth, %


Cost of goods sold

3.1 m

Gross profit

14.3 m

Gross profit Margin, %


R&D expense

26.7 m60.6 m73.9 m99.3 m

General and administrative expense

12.7 m32.7 m88.3 m186.5 m

Operating expense total

39.4 m93.4 m164.7 m290.1 m


(38.3 m)(93.2 m)(164.6 m)(272.8 m)

EBIT margin, %


Interest income

349 k755 k499 k2.8 m

Pre tax profit

(37.9 m)(92.5 m)(164.1 m)(270.1 m)

Income tax expense

330 k1.3 m

Net Income

(37.9 m)(92.5 m)(164.4 m)(271.4 m)
$, USDFY, 2013FY, 2014FY, 2015FY, 2016


11.7 m61.9 m102.1 m163.6 m

Accounts Receivable

5.9 m


1.2 m2.2 m7.5 m

Current Assets

188.4 m324.6 m219 m547.9 m


579 k553 k2.2 m3.1 m

Total Assets

189.1 m325.5 m221.9 m561.2 m

Accounts Payable

372 k2 m1.7 m3.9 m

Current Liabilities

7 m15.8 m21.9 m42.6 m

Additional Paid-in Capital

587.7 m807.6 m862.3 m1.5 b

Retained Earnings

(405.7 m)(498.1 m)(662.6 m)(934 m)

Total Equity

182.1 m309.5 m199.8 m518.4 m

Financial Leverage

1 x1.1 x1.1 x1.1 x
$, USDFY, 2014FY, 2015FY, 2016

Net Income

(92.5 m)(164.4 m)(271.4 m)

Depreciation and Amortization

206 k647 k1.8 m

Accounts Receivable

(5.9 m)


652 k(804 k)(4.7 m)

Accounts Payable

1.6 m(344 k)2.2 m

Cash From Operating Activities

(66.4 m)(121.8 m)(210.4 m)

Purchases of PP&E

(180 k)(2.1 m)(1.5 m)

Cash From Investing Activities

(87.3 m)147.6 m(261.9 m)

Long-term Borrowings

(32 k)

Cash From Financing Activities

203.9 m14.5 m533.8 m

Income Taxes Paid

415 k365 k
Y, 2016

Financial Leverage

1.1 x

ACADIA Pharmaceuticals Operating Metrics

FY, 2016

Patents Granted


ACADIA Pharmaceuticals Market Value History

ACADIA Pharmaceuticals News and Updates

ACADIA Pharmaceuticals Company Life and Culture

You may also be interested in